News

Enlarge image

BusinessUKSweden

AstraZeneca restructures

19.03.2013 - British-Swedish drugmaker AstraZeneca has announced to restructure its operations, axing 1,600 jobs and relocating 2,500 employees.

It is the third time in three years that the British-Swedish pharma company is going to restructure its R&D. The company said it will concentrate its R&D in the UK. A third of the US-$1.4bn restructuring cost will be invested in a new R&D complex in the UK, unifying the company’s small molecule and biologics research under one roof in Cambridge. About 1,600 researchers will be relocated from Alderley Park to the new site. By 2016, AstraZeneca will remove its current headquarters from London to the new Cambridge site. Steve Bates, chief of the British Industry Association applauded the decision; "I am pleased that AstraZeneca has seen the value of the UK as a global hub for bioscience and we welcome its £330 million investment in consolidating its R&D activities and its global headquarters in Cambridge.“

In the US, the company will move its Global Medicines Development Group from Wilmington to Gaithersburg, the headquarters of its biologics subsidiary MedImmune. The company announced it will axe 650 jobs in the US. Small molecule research in Sweden will remain. With the measures the drug giant aims at improving its R&D productivity, leaving three global R&D centres.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/astrazeneca-restructures.html

CommercialisationEU

10.02.2016 In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.05 CHF25.00%
  • ZEALAND PHARMA (DK)105.50 DKK14.05%
  • SARTORIUS (D)244.45 EUR12.88%

FLOP

  • PAION (D)1.25 EUR-36.55%
  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%

TOP

  • VERONA PHARMA (UK)3.30 GBP26.9%
  • IXICO (UK)35.75 GBP21.2%
  • SAREUM HOLDINGS (UK)0.30 GBP20.0%

FLOP

  • BIONOR PHARMA (N)0.81 NOK-50.6%
  • PAION (D)1.25 EUR-49.4%
  • PROTHENA PLC (IE)31.97 USD-38.0%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)24.50 SEK3123.7%
  • NICOX (F)6.80 EUR241.7%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.65 SEK-86.2%
  • BIOTEST (D)13.40 EUR-85.7%
  • EVOCUTIS (UK)0.08 GBP-69.2%

No liability assumed, Date: 11.02.2016